LIFECORE BIOMEDICAL, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
LIFECORE BIOMEDICAL, INC. (LFCR) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $479.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-05
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $479.00K.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $718.00K.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $232.00K.
- 2025-02-23: Long-Term Debt, Maturity, Remainder of Fiscal Year $231.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $479.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $718.00K 10-Q · filed 2026-05-06 |
| 2025-09-30 | $232.00K 10-Q · filed 2025-11-06 |
| 2025-02-23 | $231.00K 10-Q · filed 2025-04-03 |
| 2024-11-24 | $387.00K 10-Q · filed 2025-01-02 |
| 2024-08-25 | $580.00K 10-Q · filed 2024-10-04 |
| 2024-02-25 | $193.00K 10-Q · filed 2024-08-09 |
| 2023-11-26 | $387.00K 10-Q · filed 2024-08-09 |
| 2023-08-27 | $580.00K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |